Rafael Holdings (RFL) announced that its subsidiary Cyclo Therapeutics’ 96-week pivotal phase 3 TransportNPC study evaluating intravenous Trappsol Cyclo for the potential treatment of Niemann-Pick Disease Type C1 will continue based on the independent Data Monitoring Committee review of safety and efficacy data at the prespecified 48-week interim analysis. Additionally, the Food and Drug Administration has accepted the statistical analysis plan for the TransportNPC study. These developments underscore the company’s continuing commitment to advancing its lead investigational candidate through late-stage clinical development to support global regulatory and commercial readiness.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RFL:
- Rafael Holdings Reports Improved Financial Results and Strategic Progress
- Rafael Holdings reports Q3 EPS (19c) vs ($1.36) last year
- Rafael Holdings Completes $25M Rights Offering
- Rafael Holdings Enters Standby Purchase Agreement with Chairman
- Rafael announces revised subscription rights in connection with offering
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue